Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(5)

Published: March 1, 2025

To evaluate the current level of evidence for use psychedelics management cancer pain and associated psychological distress. Pain is a common symptom treatment. However, there are high rates undertreatment due to complex underlying biology condition, potentially decrease in opioid prescribing response epidemic. A diagnosis cancer-related can trigger levels distress throughout Cancer also be exacerbated by anxiety, depression, quality life challenges, fear death dying, as well recurrence or progression. Several pharmacologic non-pharmacologic approaches have been utilized mitigate burden with some success. remains an unmet need better symptoms. Psychedelics, such lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT), under consideration new strategies mitigating burden. Although published studies limited, regulatory hurdles decreased. Many clinical trials underway assess further behavioral counseling patients comorbidities anxiety depression. These examine both feasibility efficacy Early results promising, additional research needed understand tolerability broader populations. There improve Further required treatment Recent changes paved way increased on cancer.

Language: Английский

---

Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

As interest in using psilocybin therapy for treating mental health disorders intensifies, the need efficient production methods becomes increasingly important. Current medical-grade is inefficient and relies on a complicated multistep synthesis. This study has explored evaluated psilocin ester prodrugs salts as potential alternatives to psilocybin, focusing their ease of synthesis, chemical stability, metabolic profiles. A diverse library 15 six was synthesized evaluated. The successfully identified several that exhibited desirable characteristics, including storage handling rapid conversion psilocin, easy with advantages over psilocybin. research introduces viable options through compounds salts, offering promising avenues future development.

Language: Английский

---

Mushroom bioactives—polysaccharides to psilocybin: a viewpoint on the therapeutic use of mushrooms for consumers and patients for health and neuroplasticity

Published: Jan. 1, 2025

Abstract The use of mushrooms in health-promoting foods and substances is widely studied. There are compelling data to indicate that polysaccharides phenolic compounds derived from mushroom sources have long-lasting metabolic effects when ingested. More recently, attention has returned the traditional practices using psychotropic bioactive ingredients obtained for aid treatment trauma neuroplasticity therapeutic uses alternative health practices. While this heavily legislated not universally accepted all governments world, clinicians psychotherapy professionals reimagining safe controlled these (namely psilocybin-based compounds) management procedures. This short viewpoint article poses question, aiming create a debate potential use, as whether psilocybin could, or even should, an alchemical role play consumers patients terms medicines? What level regulation would be required? And what safeguards should implemented?

Language: Английский

---

Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review

Psychedelic Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Language: Английский

---

Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice

Psychopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 17, 2025

Language: Английский

---